Last reviewed · How we verify

NCT05924789: GASPAR

Epidemiological Characteristics of Gastric and Pancreatic Cancers in Latin America

Completed Last updated 12 February 2025
What this trial tests

trial testing Observational study in Gastric Cancer in 120 participants. Completed in 24 September 2024.

Timeline
11 August 2023
Primary endpoint
24 September 2024
24 September 2024

Quick facts

Lead sponsorLatin American Cooperative Oncology Group
StatusCompleted
Study typeOBSERVATIONAL
Enrollment120
Start date11 August 2023
Primary completion24 September 2024
Estimated completion24 September 2024
Sites6 locations across Argentina, Brazil

Drugs / interventions tested

Conditions studied

Sponsor

Latin American Cooperative Oncology Group

Who can join

18 and older, any sex, with Gastric Cancer or GastroEsophageal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Currently, there is no Brazilian or Latin American epidemiological data, such as clinical-pathological characteristics, standard treatments and outcomes of gastric cancer and pancreatic cancer in the region. The study aims to create a Latin American multicenter database to analyze epidemiological, clinical, and pathological data, treatments, outcomes, and biological information from patients with gastric and pancreatic cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Observational study

Trials testing the same drug.

Other recruiting trials for Gastric Cancer

Currently open trials in the same condition.

Other Latin American Cooperative Oncology Group trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05924789.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing